V
Valérie Vilgrain
Researcher at University of Paris
Publications - 609
Citations - 35113
Valérie Vilgrain is an academic researcher from University of Paris. The author has contributed to research in topics: Medicine & Magnetic resonance imaging. The author has an hindex of 84, co-authored 559 publications receiving 29362 citations. Previous affiliations of Valérie Vilgrain include Beaujon Hospital & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma
Peter R. Galle,Alejandro Forner,Josep M. Llovet,Vincenzo Mazzaferro,Fabio Piscaglia,Jean-Luc Raoul,Peter Schirmacher,Valérie Vilgrain +7 more
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
Journal ArticleDOI
Portal vein embolization before right hepatectomy: prospective clinical trial.
Olivier Farges,Jacques Belghiti,Reza Kianmanesh,Jean-Marc Regimbeau,Roberto Santoro,Valérie Vilgrain,Alban Denys,Alain Sauvanet +7 more
TL;DR: Before elective right hepatectomy, the hypertrophy of FLR induced by PVE had no beneficial effect on the postoperative course in patients with normal liver, and before chronic liver disease, PVE significantly decreased the incidence of postoperative complications as well as the intensive care unit stay and total hospital stay.
Journal ArticleDOI
Evaluation of Liver Diffusion Isotropy and Characterization of Focal Hepatic Lesions with Two Single-Shot Echo-planar MR Imaging Sequences: Prospective Study in 66 Patients
TL;DR: Diffusion-weighted MR imaging can help differentiate benign from malignant hepatic lesions and the use of two b values in one direction could be sufficient for the design of MR sequences in the liver.
Journal ArticleDOI
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
Valérie Vilgrain,Valérie Vilgrain,Helena Pereira,Eric Assenat,Boris Guiu,Alina Diana Ilonca,Georges-Philippe Pageaux,Annie Sibert,Mohamed Bouattour,Rachida Lebtahi,Wassim Allaham,Hélène Barraud,Valérie Laurent,Elodie Mathias,Jean-Pierre Bronowicki,Jean-Pierre Tasu,Rémy Perdrisot,Christine Silvain,René Gerolami,Olivier Mundler,Jean-François Seitz,Vincent Vidal,Christophe Aubé,Frédéric Oberti,Olivier Couturier,Isabelle Brenot-Rossi,Jean-Luc Raoul,Anthony Sarran,Charlotte Costentin,Emmanuel Itti,Alain Luciani,Alain Luciani,René Adam,Maïté Lewin,Didier Samuel,Maxime Ronot,Maxime Ronot,Aurelia Dinut,Laurent Castera,Laurent Castera,Gilles Chatellier,Gilles Chatellier,Elisabeth Delhom Christol,Alina D. Ilonca,Julie Lonjon,Mohamed Abdel-Rehim,Arnaud Dieudonné,Christophe Bazin,Carine Chagneau-Derrode,Patrick Borentain,Antoine Bouvier,Laurent Vervueren,Julia Chalaye,Hicham Kobeiter,Julien Edeline,Etienne Garin,Yan Rolland,Isabelle Archambeaud,T. Eugène,Eric Frampas,Christophe Cassinotto,Martine Guyot,Jean-Baptiste Hiriart,Bruno Lapuyade,Julien Vergniol,Philippe Bachellier,Julien Detour,Bernard Duclos,Michel Greget,Francois Habersetzer,Alessio Imperiale,Philippe Merle,Agnès Rode,Julie Morvan,Eric Nguyen-Khac,Thierry Yzet,G. Baudin,Patrick Chevallier,Abakar Mahamat,Thierry Piche,Micheline Razzouk,Patrick Hillon,Romaric Loffroy,Michel Toubeau,Julie Vincent,Gabriele Barabino,Nadia Bouarioua,Muriel Cuilleron,Marie Ecochard,Nathalie Prevot-Bitot,Vincent Leroy,J. Roux,Christian Sengel,Valérie Bourcier,Nathalie Ganne-Carrié,Olivier Seror,Sylvie Costo,Thong Dao,Jean-Pierre Pelage,Jérôme Dumortier,Francesco Giammarile,Pierre-Jean Valette,Nadia Ghazzar,Olivier Pellerin,Julien Taieb,Pierre Weinmann,Alexandra Heurgue-Berlot,Claude Marcus,Daniele Sommacale,Maria-Angéla Castilla-Lièvre,Sophie Maitre,Lysiane Marthey +111 more
TL;DR: SarAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy in patients with hepatocellular carcinoma.
Journal ArticleDOI
Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis
Valérie Paradis,Stéphane Zalinski,Emna Chelbi,Nathalie Guedj,Françoise Degos,Valérie Vilgrain,Pierre Bedossa,Jacques Belghiti +7 more
TL;DR: HCCs in patients with features of MS as the only risk factor for liver disease have distinct morphological characteristics and mainly occur in the absence of significant fibrosis in the background liver.